Related references
Note: Only part of the references are listed.Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer
Miika Sainio et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
A Small-Molecule Antagonist of the β-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis
Liang Fang et al.
CANCER RESEARCH (2016)
Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer
Pablo Maroto et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
Neal D. Shore et al.
LANCET ONCOLOGY (2016)
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Stefan Prekovic et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Modeling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling
Alessia Calcagni et al.
ELIFE (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
Eleni Efstathiou et al.
EUROPEAN UROLOGY (2015)
WNT5A Has Anti-Prostate Cancer Effects In Vitro and Reduces Tumor Growth in the Skeleton In Vivo
Stefanie Thiele et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
Qiang Dang et al.
MOLECULAR ONCOLOGY (2015)
Enzalutamide for patients with metastatic castration-resistant prostate cancer
Wijdan H. Ramadan et al.
ONCOTARGETS AND THERAPY (2015)
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Eugine Lee et al.
PLOS ONE (2015)
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Jennifer L. Bishop et al.
ONCOTARGET (2015)
Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction
G. T. Lee et al.
BRITISH JOURNAL OF CANCER (2014)
Enzalutamide: looking back at its preclinical discovery
Yun-Sok Ha et al.
EXPERT OPINION ON DRUG DISCOVERY (2014)
DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis
Yufeng Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer
Charlotte Svensson et al.
NUCLEIC ACIDS RESEARCH (2014)
Clinical Activity of Enzalutamide Versus Docetaxel in Men With Castration-Resistant Prostate Cancer Progressing After Abiraterone
Daniel L. Suzman et al.
PROSTATE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
What Are the Molecules Involved in Regulatory T-Cells Induction by Dendritic Cells in Cancer?
Rodrigo Nalio Ramos et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 Signaling
Hifzur Rahman Siddique et al.
PLOS ONE (2013)
Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling
John O. DaSilva et al.
PROSTATE (2013)
Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
Juan Miguel Mosquera et al.
NEOPLASIA (2013)
ENZALUTAMIDE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
Y-S Ha et al.
DRUGS OF TODAY (2013)
The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients
Akira Komiya et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Himisha Beltran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Elevated Level of Wnt5a Protein in Localized Prostate Cancer Tissue Is Associated with Better Outcome
Azharuddin Sajid Syed Khaja et al.
PLOS ONE (2011)
Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes
Ana Aparicio et al.
CANCER DISCOVERY (2011)
The Neuroendocrine-Derived Peptide Parathyroid Hormone-Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor
John DaSilva et al.
CANCER RESEARCH (2009)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
Neuroendocrine differentiation in the progression of prostate cancer
Akira Komiya et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih-Min A. Huang et al.
NATURE (2009)
Small cell carcinoma of the prostate - A morphologic and immunohistochemical study of 95 cases
Wenle Wang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Crosstalk between the Androgen Receptor and beta-Catenin in Castrate-Resistant Prostate Cancer
Gang Wang et al.
CANCER RESEARCH (2008)
An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells
Hongbo Wang et al.
JOURNAL OF CELL SCIENCE (2008)
Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer
K. Suzuki et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2007)
Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells
Ta-Chun Yuan et al.
ENDOCRINE-RELATED CANCER (2007)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Wnt signalling in stem cells and cancer
T Reya et al.
NATURE (2005)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex
M Lepourcelet et al.
CANCER CELL (2004)
The development of androgen-independent prostate cancer
BJ Feldman et al.
NATURE REVIEWS CANCER (2001)
Share Paper
